logo
The simple bedroom trick to help you sleep better during a heatwave – as doctor warns of common mistake

The simple bedroom trick to help you sleep better during a heatwave – as doctor warns of common mistake

The Sun18-06-2025
CREATING the perfect bedroom temperature is key for sleeping better through hot summer nights.
And it can all come down to the precise position of your door, according to a sleep specialist.
2
With temperatures set to exceed 30C in some parts of the England by the weekend, many Brits will be facing an uncomfortable night's rest.
But the way bedroom doors within sleeping spaces are positioned affects airflow patterns, says Dr Jordan Burns from AmeriSleep.
Depending on the angle chosen, it can create cooling cross-ventilation or trap heat.
"Most people focus solely on windows for cooling, but bedroom doors control how air circulates throughout your sleeping space," Dr Burns said.
"A properly positioned door can make the difference between restful sleep and hours of uncomfortable tossing and turning."
Dr Burns recommends keeping bedroom doors fully open during daytime hours if the rest of the home is cooler, allowing for maximum air exchange between spaces.
This approach works particularly well for rooms that receive direct sunlight.
"When outside temperatures climb higher than those inside your home, keeping your bedroom door wide open allows cooler air from north-facing rooms to circulate throughout," he said.
"This creates a natural current that pushes hot air up and out while drawing cooler air in from below."
For night-time cooling, however, he recommends a more precise approach to door positioning.
Five best stretches to improve sleep
"The optimal angle for a bedroom door at night is approximately 45 degrees," Dr Burns explained.
"This specific position creates what fluid dynamics calls a 'venturi effect' that accelerates airflow through the narrower opening, pulling hot air out more efficiently than a fully open door would."
Many people make the common mistake of either leaving doors completely open or fully closed during hot weather.
But a completely open door actually slows down airflow in many cases because the opening is too large to create the pressure differentials that drive air movement, said Dr Burns.
He added: "Conversely, a fully closed door prevents any air exchange, trapping heat and moisture that build up while you sleep."
And door positioning must work together with window management for maximum cooling effect.
"If your windows and door create a straight-line path, you'll generate the strongest possible airflow through your bedroom," Dr Burns said.
"The ideal setup in UK homes is having your bedroom door at 45 degrees with windows open on the opposite wall, creating a direct pathway for air movement."
Furniture placement in relation to door positioning is also important.
He also advised keeping furniture at least 30cm away from the door swing path.
Tall wardrobes or dressers near doors can block airflow and create stagnant air pockets where heat accumulates.
For flats and apartments where cross-ventilation options are limited, Dr Burns recommends changing door positions throughout the day based on sun exposure and temperature variations.
"In single-aspect flats, try keeping your bedroom door closed during the day if that room receives direct sunlight," he said.
"Then open it to precisely 45 degrees at night when the rest of the flat has cooled down."
Research from the Ministry of Housing, Communities and Local Government found that certain homes are particularly vulnerable to overheating, including "flats on the top floor because heat rises" and "homes with opening windows on just one side of the property, as this means there is less ventilation through the home."
Dr Burns pointed out that proper door positioning can help address these exact vulnerabilities.
"For top floor flats, keeping bedroom doors positioned at 45 degrees at night helps draw cooler air up from lower levels of the building," he said.
"For single-aspect properties, strategically angling your bedroom door creates a secondary airflow path that compensates for the lack of cross-ventilation from windows."
And the sleep expert suggests a simple method to test if your door positioning is working effectively for bedroom cooling.
"Place a lightweight ribbon or tissue near the gap between the door and frame," he explained.
"If it moves toward the door, you're successfully drawing air through the room. If it remains still or moves away, adjust your window and door configuration until you achieve proper airflow.
"Good sleep remains possible during hot weather if you understand how to control airflow in your home.
"Door positioning is a cost-free intervention that can improve your sleeping environment while reducing both energy costs and environmental impact compared to mechanical cooling options."
Other ways to keep cool at night during the heat
Use fans
Strategically position fans to circulate air, potentially placing a tray of ice in front of it for a cooling effect.
Cool down your bed
Consider using a thin cotton sheet, chilling socks in the fridge, or even freezing your sheets briefly.
Take a cool shower or bath
Taking a lukewarm or cool shower or bath before bed can help lower your body temperature.
Stay hydrated
Drink plenty of water throughout the day and night, but avoid excessive amounts right before bed to prevent waking up.
Wear light clothing to bed
Opt for loose-fitting, breathable fabrics like cotton.
Consider your sleeping position
Sleeping on your side can help with heat dissipation.
Avoid alcohol and caffeine
These can disrupt sleep and dehydrate you, making it harder to stay cool.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New NHS bladder cancer treatment doubles survival time
New NHS bladder cancer treatment doubles survival time

Sky News

time22 minutes ago

  • Sky News

New NHS bladder cancer treatment doubles survival time

The NHS will roll out a new treatment for advanced bladder cancer which doubles survival time. It's estimated that 1,250 people a year could benefit from a combination of drugs called enfortumab vedotin and pembrolizumab. The first is an antibody-drug also known as Padcev, made by Astellas and Pfizer, while the latter is a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest the combo leads to improved survival compared to platinum-based chemotherapy - increasing from an average of around 16 months to almost 34. Researchers also found people survive for longer without their disease worsening, also known as progression-free survival - going up from six months to more than a year. It will mark the first significant change to treatment of advanced bladder cancer since the 1980s, according to expert Professor Thomas Powels, director of Barts Cancer Institute Biomedical Research Centre (QMUL). Around 18,000 people in England are diagnosed with bladder cancer each year. The new treatment was approved for NHS use by the National Institute for Health and Care Excellence, which said it was "highly promising" and could make a "tremendous difference" to people. One patient who took part in the trial said it had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, said: "I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. "I am going to have an extra few years to see my grandson grow up - and maybe even be around to see him get married."

Blood matching test to be offered to patients with rare conditions
Blood matching test to be offered to patients with rare conditions

The Independent

timean hour ago

  • The Independent

Blood matching test to be offered to patients with rare conditions

The health service has launched a personalised 'blood matching' test for people with rare conditions who require regular blood transfusions. The move will allow donor blood to be matched to these patients more closely, to reduce the risk of severe reactions. The new test uses genetics to generate detailed blood group information. It is the first time it has been used for patients with rare inherited anaemias – with around 300 people eligible for testing, according to NHS Blood and Transplant (NHSBT). The programme has been backed by the family of toddler Woody Mayers, aged 22 months, who has a rare inherited anaemia called congenital dyserythropoietic anaemia (CDA) type 1. The condition causes the bone marrow to struggle to produce healthy red blood cells, which carry oxygen around the body. It is estimated to affect between one to five out of every million babies. Patients have low haemoglobin levels, meaning Woody relies on blood transfusions every four weeks to stay alive. However, the donor blood must be carefully matched to reduce the risk of patient's developing antibodies against certain blood types, which can cause severe reactions and make transfusions more difficult in the future. The new genotyping testing programme, a partnership between NHSBT and NHS England, uses genetics to identify more of the rarer blood groups. Samples are collected at routine hospital appointments, with patients' DNA tested to find out their blood types. About 300 people with transfusion dependent, rare inherited anaemias, are eligible for the test. All patients with sickle cell disorder and thalassaemia are also eligible, even if they do not rely on blood transfusions. Kate Downes, head of genomics at NHSBT, said: 'The new genotyping test can test blood groups faster and more extensively than standard testing methods.' Professor Dame Sue Hill, chief scientific officer at NHS England, said: 'The power of genomics is transforming medicine, with extended blood group genotyping now being utilised to help patients, especially those requiring regular transfusions. 'This is an exceptional example of an evidence-based innovation, developed from genetic data, being used to drive forward improvements that will make a huge difference across the NHS. 'Blood donations can be lifesaving for patients, and the NHS needs a constant flow of donations to provide people with the best possible care, so I'd encourage anyone who can donate to do so.' Woody's family were alerted to potential health conditions at a 20-week pregnancy scan. He was born prematurely at 34 weeks with haemoglobin levels around a quarter of what they should have been. Woody's mother Polly Mayers, 35, from Robertsbridge in East Sussex, said: 'When he was born, he was very poorly and pale. He didn't cry for a few minutes. He needed ventilation breaths. It was really frightening. 'The first few days were very critical for Woody. He was extremely unwell. Nobody knew the cause for his haemolytic anaemia.' The toddler has now being having regular transfusions fore more than a year, receiving 140mls of red blood cells every four weeks to boost his haemoglobin. Despite this, his family describes him as an energetic little boys who likes trips to the park and riding his bike. His mother added: 'Woody will need the blood to be well-matched so that his transfusions don't become too difficult or risky. 'The test will help him and anyone else with a similar condition. I hope everyone eligible gets it.' Ms Downes said: 'Woody has very rare disorder and he relies on blood transfusions to stay alive but these need to be well matched. 'We want everyone eligible, like Woody, to be tested so they can get better matched blood. We also need more people to donate, so we can supply the matched lifesaving blood to Woody and people like him.' Woody's family are also urging people to donate blood. Mrs Mayers, a community matron, said: 'There's no way to sugar-coat it – if it wasn't for blood donors, Woody would not be alive. 'I'm incredibly grateful to blood donors for ensuring blood is available when he needs it.'

First new treatment for advanced bladder cancer in decades given green light
First new treatment for advanced bladder cancer in decades given green light

The Independent

time4 hours ago

  • The Independent

First new treatment for advanced bladder cancer in decades given green light

A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store